Drugs / Melanotan II
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07437560 | Feb 2026 → Feb 2027 expected | vitiligo | Hudson Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Melanotan II | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07437560 ↗ |
| Known as | MT-II | “Melanotan II (MT-II) is a synthetic cyclic melanocortin receptor agonist with activity at melanocortin receptors involved in melanogenesis (pigment production).” NCT07437560 ↗ |
| Action | Activate | “synthetic cyclic melanocortin receptor agonist” NCT07437560 ↗ |